Clinical Trial Update: Darolutamide in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating darolutamide added to standard androgen deprivation therapy and docetaxel in metastatic hormone-sensitive prostate cancer has completed…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hormone-sensitive Prostate Cancer

Drugs mentioned

• Nubeqa (darolutamide)
• Taxotere (docetaxel)

Snippet

Sponsor: Bayer | Conditions: Metastatic Hormone-sensitive Prostate Cancer | Phase 3 | Status: COMPLETED | Results posted: 2023-02-24